GlassScriptPhysician profile
Jake H Mckay
NPI 1497166425
$46,324.85
in general payments reported to CMS, 2019-2025
51 companies · $3,679 in 2025
The $3,679 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,864 · 2020: $660 · 2021: $11K · 2022: $5,044 · 2023: $12K · 2024: $12K · 2025: $3,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $6,115 · Travel and Lodging: $468 · Education: $20.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,460.00 |
| Food and Beverage | $6,114.79 |
| Travel and Lodging | $467.89 |
| Education | $20.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $36,461.98 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Neuropace, INC. | $1,757.75 | 2019-2021 | |
| Abbvie INC. | $1,517.82 | 2022-2025 | |
| Cgg Medical INC | $1,200.00 | 2021 | |
| Neurelis, INC. | $619.19 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $437.33 | 2022-2025 | |
| Sk Life Science, INC. | $362.16 | 2020-2024 | |
| Pfizer INC. | $286.61 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $271.82 | 2023-2024 | Aptiom |
| Teva Pharmaceuticals USA, INC. | $262.46 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $202.23 | 2020-2022 | |
| Lundbeck LLC | $200.08 | 2020-2025 | Vyepti |
| Argenx US, INC. | $178.71 | 2022-2025 | Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $165.44 | 2021-2022 | |
| Tanabe Pharma America, INC. | $156.78 | 2020-2025 | Radicava |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Mckay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.